Skip to main content

Table 2 Results of efficacy measures at last observation

From: A double-blind randomized study assessing safety and efficacy following one-year adjunctive treatment with bitopertin, a glycine reuptake inhibitor, in Japanese patients with schizophrenia

  Negative symptom Sub-optimally controlled symptom
5 mg (n = 10) 10 mg (n = 47) 20 mg (n = 48) 5 mg (n = 5) 10 mg (n = 25) 20 mg (n = 25)
PANSS, mean (SD)
 Total score
  Baseline 78.8 (9.9) 79.7 (10.3) 80.5 (7.4) 87.2 (10.4) 88.4 (12.2) 91.0 (13.6)
  Change −7.7 (5.7) −11.0 (12.5) −10.3 (15.9) −9.4 (12.7) −11.0 (14.0) −7.5 (14.6)
 Negative symptom factor score
  Baseline 25.9 (4.5) 26.7 (4.7) 26.8 (4.4) 22.2 (6.2) 22.6 (5.7) 24.2 (6.4)
  Change −4.8 (4.1) −4.9 (4.7) −4.9 (6.0) −1.6 (3.7) −3.7 (4.9) −2.5 (4.8)
 Positive symptom factor score
  Baseline 16.9 (3.3) 17.3 (3.5) 18.0 (3.2) 26.2 (6.0) 26.4 (3.8) 26.5 (5.1)
  Change −0.9 (0.9) −1.7 (2.8) −1.4 (3.8) −4.2 (5.0) −3.9 (4.5) −2.1 (5.9)
 Disorganized thought/cognition factor score
  Baseline 19.3 (2.5) 19.3 (4.3) 19.2 (3.0) 18.2 (2.9) 19.2 (3.7) 20.8 (4.8)
  Change −1.7 (1.9) −2.5 (3.2) −2.3 (3.6) −1.8 (1.8) −1.8 (3.0) −1.4 (3.0)
 Uncontrolled hostility/excitement factor score
  Baseline 6.5 (2.0) 7.1 (2.4) 7.0 (2.3) 10.4 (4.4) 9.5 (3.2) 9.0 (2.5)
  Change 0.5 (1.2) −0.6 (1.6) −0.5 (2.2) −1.0 (1.4) −0.9 (2.3) −0.7 (2.0)
 Anxiety/depression factor score
  Baseline 10.2 (2.4) 9.3 (2.6) 9.6 (2.8) 10.2 (2.5) 10.7 (2.7) 10.5 (2.8)
  Change −0.8 (1.2) −1.3 (2.2) −1.3 (2.3) −0.8 (1.9) −0.8 (2.1) −0.9 (2.5)
 Responder in each symptoma, n (%) 6 (60) 27 (57) 23 (49) 2 (40) 14 (56) 7 (28)
CGI, mean (SD)
 CGI-S of overall symptom
  Baseline 3.6 (0.5) 4.1 (0.6) 4.2 (0.6) 4.2 (0.4) 4.2 (0.5) 4.4 (0.6)
  Change −0.1 (0.3) −0.6 (0.9) −0.6 (1.2) −1.0 (1.0) −0.8 (1.0) −0.6 (1.0)
 CGI-S in each symptom
  Baseline 4.4 (0.7) 4.4 (0.6) 4.5 (0.7) 4.2 (0.4) 4.3 (0.6) 4.3 (0.6)
  Change −0.8 (1.0) −0.8 (1.0) −0.9 (1.2) −0.8 (1.1) −0.9 (1.2) −0.6 (1.2)
 CGI-I of overall symptomb, n (%) 0 (0) 8 (17) 12 (26) 1 (20) 7 (28) 3 (12)
 CGI-I in each symptomb, n (%) 2 (20) 9 (19) 12 (26) 1 (20) 6 (24) 4 (16)
PSP total score, mean (SD)
  Baseline 54.0 (16.2) 50.0 (14.2) 46.5 (16.0) 45.4 (18.8) 48.8 (15.6) 46.1 (12.5)
  Change 7.2 (7.3) 7.3 (11.1) 7.0 (13.8) 10.6 (14.4) 5.0 (7.4) 6.8 (11.6)
  1. Abbreviations: CGI clinical global impression, CGI-I CGI-improvement, CGI-S CGI-severity of illness, PANSS positive and negative syndrome scale, PSP personal and social performance, SD standard deviation
  2. a20 % or greater improvement of PANSS negative symptom factor score in the negative symptom group or of PANSS positive symptom factor score in the sub-optimally controlled symptom group. The scores in each item were transformed from 1–7 to 0–6
  3. bResponder of CGI-I is defined as a patient has a response of “very much improved” or “much improved”